| 11/04/24 | 07:00:14 | 11 Apr 2024 | | AstraZeneca increases 2024 dividend by 7% |
| 08/04/24 | 07:00:07 | 8 Apr 2024 | | Enhertu approved in US for HER2+ solid tumours |
| 05/04/24 | 07:00:07 | 5 Apr 2024 | | Imfinzi improved OS & PFS in limited-stage SCLC |
| 02/04/24 | 15:00:00 | 2 Apr 2024 | | Total Voting Rights |
| 02/04/24 | 07:05:01 | 2 Apr 2024 | | Voydeya approved in US |
| 02/04/24 | 07:00:12 | 2 Apr 2024 | | FDA accepts Dato-DXd BLA for breast cancer |
| 25/03/24 | 07:00:05 | 25 Mar 2024 | | Ultomiris approved in the US for NMOSD |
| 19/03/24 | 07:00:09 | 19 Mar 2024 | | AstraZeneca to acquire Fusion |
| 14/03/24 | 07:00:10 | 14 Mar 2024 | | AstraZeneca to acquire Amolyt |
| 12/03/24 | 11:00:00 | 12 Mar 2024 | | Director/PDMR Shareholding |
| 07/03/24 | 11:00:01 | 7 Mar 2024 | | Notice of AGM |
| 06/03/24 | 15:05:00 | 6 Mar 2024 | | Director/PDMR Shareholding |
| 06/03/24 | 15:00:01 | 6 Mar 2024 | | Director/PDMR Shareholding |
| 04/03/24 | 07:00:06 | 4 Mar 2024 | | EMA validates Dato-DXd MAAs for NSQ NSCLC and BC |
| 01/03/24 | 15:00:00 | 1 Mar 2024 | | Total Voting Rights |
| 26/02/24 | 07:00:01 | 26 Feb 2024 | | Voydeya recommended for EU approval |
| 22/02/24 | 13:15:00 | 22 Feb 2024 | | Acquisition of Gracell completed |
| 22/02/24 | 11:00:00 | 22 Feb 2024 | | Director/PDMR Shareholding |
| 22/02/24 | 07:00:06 | 22 Feb 2024 | | AstraZeneca prices a $5bn bond offering |
| 21/02/24 | 07:00:03 | 21 Feb 2024 | | Filing of Form 20-F with SEC |
| 20/02/24 | 11:00:00 | 20 Feb 2024 | | Annual Financial Report |
| 19/02/24 | 15:00:01 | 19 Feb 2024 | | AstraZeneca completes acquisition of Icosavax |
| 19/02/24 | 07:10:01 | 19 Feb 2024 | | Tagrisso plus chemo approved in US for lung cancer |
| 19/02/24 | 07:05:00 | 19 Feb 2024 | | FDA accepts Dato-DXd BLA for nonsquamous NSCLC |
| 19/02/24 | 07:00:04 | 19 Feb 2024 | | Tagrisso improved PFS in Stage III lung cancer |
| 08/02/24 | 07:00:07 | 8 Feb 2024 | | Final Results |
| 01/02/24 | 15:00:00 | 1 Feb 2024 | | Total Voting Rights |
| 02/01/24 | 15:00:01 | 2 Jan 2024 | | Total Voting Rights |
| 27/12/23 | 07:00:03 | 27 Dec 2023 | | AstraZeneca acquires Gracell |
| 22/12/23 | 07:00:05 | 22 Dec 2023 | | Wainua (eplontersen) granted first US FDA approval |
| 14/12/23 | 15:00:02 | 14 Dec 2023 | | Director/PDMR Shareholding |
| 12/12/23 | 07:05:00 | 12 Dec 2023 | | AstraZeneca to acquire Icosavax |
| 01/12/23 | 15:05:00 | 1 Dec 2023 | | Block listing Interim Review |
| 01/12/23 | 15:00:01 | 1 Dec 2023 | | Total Voting Rights |
| 01/12/23 | 07:00:06 | 1 Dec 2023 | | Discontinuation of two CRYSTALIZE evidence trials |
| 23/11/23 | 15:00:00 | 23 Nov 2023 | | Director/PDMR Shareholding |
| 17/11/23 | 07:00:11 | 17 Nov 2023 | | Truqap approved in US for HR+ breast cancer |
| 14/11/23 | 07:05:01 | 14 Nov 2023 | | Update on PACIFIC-2 Phase III trial for Imfinzi |
| 09/11/23 | 15:00:00 | 9 Nov 2023 | | Director Declaration |
| 09/11/23 | 07:10:01 | 9 Nov 2023 | | Imfinzi combination improves PFS in liver cancer |
| 09/11/23 | 07:05:00 | 9 Nov 2023 | | Agreement with Eccogene for clinical stage GLP-1RA |
| 09/11/23 | 07:00:16 | 9 Nov 2023 | | 9M and Q3 2023 results |
| 01/11/23 | 15:00:00 | 1 Nov 2023 | | Total Voting Rights |
| 01/11/23 | 07:00:12 | 1 Nov 2023 | | AstraZeneca cell & gene therapy deal w/ Cellectis |
| 03/10/23 | 07:00:08 | 3 Oct 2023 | | AstraZeneca settles Nexium liability litigations |
| 02/10/23 | 15:00:02 | 2 Oct 2023 | | Total Voting Rights |
| 22/09/23 | 07:00:04 | 22 Sept 2023 | | Dato-DXd improved PFS in breast cancer |
| 20/09/23 | 07:00:05 | 20 Sept 2023 | | Alexion completes Pfizer gene therapy agreement |
| 15/09/23 | 15:00:01 | 15 Sept 2023 | | Enhertu recommended in EU for HER2-mutant NSCLC |
| 11/09/23 | 16:00:01 | 11 Sept 2023 | | Fasenra Phase III EGPA trial met primary endpoint |
